Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Silverberg JI, Rosmarin D, Bieber T, Chovatiya R, Gooderham M, Gkalpakiotis S, Reich A, Murrell DF, Skibinska J, Sadick N, Blajić I, Tsianakas A, Fernandez-Penas P, Kern JS, Montero-Vílchez T, Popov TA, Kurian A, Sauder MB, Laquer VT, Chaudhry S, Lee ZH, Hannaway M, Yu D, Liu Y, Fanton C, Lu H, Kotzin B, Tagliaferri M, Zalevsky J, Warren RB, REZOLVE-AD Study Investigators

Open source

DOI: 10.1016/s0140-6736(26)01143-8
Published: 2026 Aug 29
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01143-8,
  title = {Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.},
  author = {Silverberg JI and Rosmarin D and Bieber T and Chovatiya R and Gooderham M and Gkalpakiotis S and Reich A and Murrell DF and Skibinska J and Sadick N and Blajić I and Tsianakas A and Fernandez-Penas P and Kern JS and Montero-Vílchez T and Popov TA and Kurian A and Sauder MB and Laquer VT and Chaudhry S and Lee ZH and Hannaway M and Yu D and Liu Y and Fanton C and Lu H and Kotzin B and Tagliaferri M and Zalevsky J and Warren RB and REZOLVE-AD Study Investigators},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01143-8},
  url = {https://doi.org/10.1016/s0140-6736(26)01143-8}
}

RIS

TY  - JOUR
TI  - Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.
AU  - Silverberg JI
AU  - Rosmarin D
AU  - Bieber T
AU  - Chovatiya R
AU  - Gooderham M
AU  - Gkalpakiotis S
AU  - Reich A
AU  - Murrell DF
AU  - Skibinska J
AU  - Sadick N
AU  - Blajić I
AU  - Tsianakas A
AU  - Fernandez-Penas P
AU  - Kern JS
AU  - Montero-Vílchez T
AU  - Popov TA
AU  - Kurian A
AU  - Sauder MB
AU  - Laquer VT
AU  - Chaudhry S
AU  - Lee ZH
AU  - Hannaway M
AU  - Yu D
AU  - Liu Y
AU  - Fanton C
AU  - Lu H
AU  - Kotzin B
AU  - Tagliaferri M
AU  - Zalevsky J
AU  - Warren RB
AU  - REZOLVE-AD Study Investigators
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01143-8
UR  - https://doi.org/10.1016/s0140-6736(26)01143-8
ER  -

APA

JI, S., D, R., T, B., R, C., M, G., S, G., A, R., DF, M., J, S., N, S., I, B., A, T., P, F., JS, K., T, M., TA, P., A, K., MB, S., VT, L., S, C., ZH, L., M, H., D, Y., Y, L., C, F., H, L., B, K., M, T., J, Z., RB, W., & Investigators, R. S. (2026). Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01143-8

Source records

pubmed · retrieved 2026-09-26T10:39:01.891Z